We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SCIOS TO BEGIN INTERNATIONAL TRIAL OF NATRECOR

SCIOS TO BEGIN INTERNATIONAL TRIAL OF NATRECOR

June 5, 2006

Scios, a division of Johnson & Johnson (J&J), has announced plans to launch a large-scale international study, involving upwards of 7,000 patients, to further assess the benefits and safety profile of its cardiovascular drug Natrecor in people with acutely decompensated heart failure (DHF). The program, when completed, will be the largest and most comprehensive study of its kind, the company reported.

The upcoming trial will be conducted at centers in the U.S., Canada and Europe, and will evaluate improvement in dyspnea, rehospitalization, mortality, renal effects, quality of life and pharmacoeconomics. Patient enrollment is expected to begin in the first quarter of 2007, the company said.

Natrecor (nesiritide), approved by the FDA in 2001, is currently indicated for intravenous treatment of patients with DHF who have dyspnea -- shortness of breath -- either at rest or with minimal activity.

The drug has been under scrutiny during the past year. An article published in the Journal of the American Medical Association in April 2005 (DID, April 21, 2005) indicated the drug was associated with an 80 percent increase in the risk of mortality one month after treatment compared with conventional therapies. In July 2005, prompted by these study results, the U.S. Attorney's Office in Boston issued Scios a subpoena requesting documents related to the sales and marketing of the drug.

Subsequently, the FDA requested more information about the drug's risks, and asked that further trials be conducted. The company complied with these directives, and launched a physician education program for the drug.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing